LICENSE AGREEMENTLicense Agreement • April 21st, 2004 • Auxilium Pharmaceuticals Inc • Delaware
THIS LICENSE AGREEMENT is made as of the 31st day of May, 2001 by and between BENTLEY PHARMACEUTICALS, INC., a Delaware corporation, with offices at 65 Lafayette Road, 3rd Floor, North Hampton, New Hampshire 03862-2403 (hereinafter, “BENTLEY” or “Licensor”), and AUXILIUM A2, INC., a Delaware corporation having a principal place of business at 160 W. Germantown Pike, Suite D-5, East Norriton, Pennsylvania 19401 (hereinafter, “AUXILIUM” or” Licensee”). BENTLEY and AUXILIUM may be referred to as a “Party” or, collectively, as “Parties.”
LICENSE AGREEMENTLicense Agreement • April 21st, 2004 • Auxilium Pharmaceuticals Inc • Delaware
THIS LICENSE AGREEMENT is made as of the 31st day of May, 2000 by and between BENTLEY PHARMACEUTICALS, INC., a Delaware corporation, with offices at 65 Lafayette Road, 3rd Floor, North Hampton, New Hampshire 03862-2403 (hereinafter, “BENTLEY” or “Licensor”), and AUXILIUM A2, INC., a Delaware corporation having a principal place of business at 160 W. Germantown Pike, Suite D-5, East Norriton, Pennsylvania 19401 (hereinafter, “AUXILIUM” or” Licensee”). BENTLEY and AUXILIUM may be referred to as a “Party” or, collectively, as “Parties.”
LICENSE AGREEMENTLicense Agreement • April 21st, 2004 • Auxilium Pharmaceuticals Inc • Delaware
THIS LICENSE AGREEMENT is made as of the 20th day of June, 2003 by and between Formulation Technologies, L.L.C., a Texas limited liability company, d/b/a PharmaForm with offices at 1006 East Yager Lane, Building D, Suite 101, Austin, Texas 78753 (hereinafter, “Licensor”), and AUXILIUM PHARMACEUTICALS, INC., a Delaware corporation having a principal place of business at 160 W. Germantown Pike, East Norriton, Pennsylvania 19401 (hereinafter, “AUXILIUM” or” Licensee”). Licensor and Licensee may be referred to as a “Party” -or, collectively, as “Parties.”
Distribution AgreementDistribution Agreement • April 21st, 2004 • Auxilium Pharmaceuticals Inc
RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • April 21st, 2004 • Auxilium Pharmaceuticals Inc • Texas
THIS RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is made as of the 20th day of June, 2003, by and between FORMULATION TECHNOLOGIES L.L.C., d/b/a PharmaForm, with an office located at 1006 Yeager Lane, Bldg. D, Suite 101, Austin TX 78753 (“PharmaForm”), and AUXILIUM PHARMACEUTICALS, INC. with an office located at 160 W. Germantown Pike, Norristown, PA 19401 (“AUXILIUM”).
First Amendment to Manufacturing Agreement between DPT Laboratories, Ltd. and Auxilium Pharmaceuticals, Inc.Manufacturing Agreement • April 21st, 2004 • Auxilium Pharmaceuticals Inc
This First Amendment to Manufacturing Agreement (“First Amendment”) between DPT Laboratories, Ltd. (“DPT”) and Auxilium Pharmaceuticals, Inc. (“COMPANY”) is made this 28th day of May, 2002.
LICENSE AND DISTRIBUTION AGREEMENTLicense and Distribution Agreement • April 21st, 2004 • Auxilium Pharmaceuticals Inc
THIS LICENSE AND DISTRIBUTION AGREEMENT (the “Agreement”), effective as of March 26, 2004 (the “Effective Date”) is entered into by and between Auxilium Pharmaceuticals, Inc. (“Auxilium”), a company incorporated under the laws of Delaware with offices at 160 W. Germantown Pike, Norristown, PA 19401, USA, and Ipsen Farmaceutica B.V. (“Ipsen”), a company incorporated under the laws of The Netherlands having a registered office at Hoofdweg Oostzijde 620, NL-2132 MJ Hoofddorp.
SHORT FORM GROSS LEASE BRANDYWINE NORRITON, L.P. Landlord and AUXILIUM A2, INC. Tenant for Suite D-5 East Norriton, PA 19401Auxilium Pharmaceuticals Inc • April 21st, 2004 • Pennsylvania
THIS LEASE (“Lease”) entered into as of the 28th day of February, 2000, between BRANDYWINE NORRITON, L.P., a Delaware limited partnership (“Landlord”), and AUXILIUM A2, INC., a Delaware corporation with its principal place of business at 160 West Germantown Pike, Suite D-5, East Norriton, PA 19401 (“Tenant”).
AUXILIUM PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • April 21st, 2004 • Auxilium Pharmaceuticals Inc • Delaware
THIS THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is entered into as of October 31, 2003, by and among Auxilium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the holders of the Company’s Series A Preferred Stock, par value $0.01 per share (the “Series A Preferred Stock”), set forth on Exhibit A (the “Series A Investors”), the holders of the Company’s Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), set forth on Exhibit B (the “Series B Investors”), the holders of the Company’s Series C Preferred Stock, par value $0.01 per share (the “Series C Preferred Stock”), set forth on Exhibit C (the “Series C Investors”) and the holders of the Company’s Series D Preferred Stock, par value $0.01 per share (the “Series D Preferred Stock”), set forth on Exhibit D (the “Series D Investors”).
AUXILIUM PHARMACEUTICALS, INC. LOAN AND SECURITY AGREEMENTLoan and Security Agreement • April 21st, 2004 • Auxilium Pharmaceuticals Inc • California
This LOAN AND SECURITY AGREEMENT is entered into as of March 11, 2004, by and between COMERICA BANK (“Bank”) and AUXILIUM PHARMACEUTICALS, INC. (“Borrower”).
ContractManufacturing Agreement • April 21st, 2004 • Auxilium Pharmaceuticals Inc • Texas
** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.
